Recall of various branded Bacon & Cabbage Dinners produced by Ballymaguire Foods due to the possible presence of Listeria monocytogenes
Alert SummarydatedMonday, 30 June 2025.
Category 1: For Action Alert Notification: 2025.32 Product Identification: Please see table below. Batch Code: All pack sizes, all batch codes and all use by dates. Country Of Origin: Ireland
Message: The below Bacon & Cabbage Dinners are being recalled due to the possible presence of Listeria monocytogenes. Recall notices will be displayed at points-of-sale.
Product Name.
Approval Number.
CentraBacon & Cabbage Dinner.
4008.
From The FarmBacon & Cabbage Dinner.
4008.
Good FoodBacon & Cabbage Dinner.
4008.
SuperValuBacon & Cabbage Dinner.
4008.
TescoBacon & Cabbage Dinner.
4008.
Nature Of Danger: Symptoms of Listeria monocytogenes infection can include mild flu-like symptoms, or gastrointestinal symptoms such as nausea, vomiting and diarrhoea. In rare cases, the infection can be more severe, causing serious complications. Some people are more vulnerable to Listeria monocytogenes infections, including pregnant women, babies, and people with weakened immune systems, including the elderly. The incubation period (time between initial infection and first symptoms appearing) is on average 3 weeks but can range between 3 and 70 days.
Action Required by Manufacturers, Wholesalers, Distributors, Caterers & Retailers:
Retailers: Same are requested to remove the implicated Bacon & Cabbage Dinners from sale and display recall notices at point-of-sale. Wholesalers/Distributors: Same are requested to contact their affected customers and recall the implicated Bacon & Cabbage Dinners and provide a point-of-sale recall notice to their retailer customers. Caterers: Same should not use the implicated Bacon & Cabbage Dinners. Consumers: Same are advised not to eat the implicated Bacon & Cabbage Dinners.
Final Implementation Plan For Zero Tolerance Strategy On Domestic, Sexual & Gender-Based Violence Published.
Priority areas include expanding refuge accommodation, advancing legislative reform, and cross-sectoral training initiatives for frontline professionals.
There are 95 actions in total across the strategy’s four pillars of protection, prevention, prosecution and policy co-ordination.
A robust monitoring and reporting framework establishes performance indicators to track progress and understand impact.
A targeted implementation plan for the final phase of Zero Tolerance, the Third National Strategy on Domestic, Sexual and Gender-Based Violence (DSGBV) has been published.
The implementation plan contains 95 actions across the strategy’s four pillars of Protection, Prevention, Prosecution and Policy Co-ordination, with a strong focus on delivery and collective action to 2026.
The DSGBV Agency Cuan worked in collaboration with officials from the Department of Justice and in close consultation with other Government Departments, state agencies and external stakeholders to develop the plan for 2025-2026.
Priority areas include continuing national leadership and cross government alignment, expanding refuge accommodation, delivering a comprehensive national emergency domestic violence accommodation plan, and advancing legislative reform. That legislative reform includes removing the guardianship rights of a person who has been convicted of killing their intimate partner; developing a mechanism to ensure any person in an intimate relationship can be informed if their partner has a history of domestic violence; and advancing provisions to ensure counselling records are only released where the Court decides that they contain material relevant to legal proceedings.
The plan also includes actions to continue to deliver impactful awareness campaigns on sexual consent and pathways to safety, and a comprehensive set of training actions to upskill front-line professionals across the health and social care sector, DSGBV services, the judiciary, courts and other justice agencies.
The development of the plan was collaborative and evidence informed, involving research and a review of implementation to date, followed by in-depth consultations with Government departments and state agencies. It takes an intersectional approach, ensuring that actions and outcomes are responsive to the diverse and overlapping identities of victims and survivors of DSGBV, supported by the development and establishment of survivor-centred structures to ensure that victim/survivor voice is heard. The work to develop foundational structures, build networks and relationships lays the groundwork for beginning the transition to a Fourth National Strategy on DSGBV.
Also published today is the second 2024 Progress Report, covering the period July to December 2024, which highlights continued progress across government and the sector in implementing the Zero Tolerance strategy.
Notable achievements during the reporting period include:
Expanding emergency accommodation capacity including launch of a state-of-the-art refuge facility in Wexford and strengthening the pipeline for refuge and safe home expansion.
Reform of the Social, Personal and Health Education (SPHE) Curriculum to empower students to be healthy and resilient young adults who have the skills and confidence to nurture healthy relationships.
Expansion of services for children and young people experiencing domestic or sexual violence, with €17m in funding distributed to 60 services supporting children and young people.
Enactment of the Family Courts Act 2024 providing for the establishment of family court divisions within the existing court structures including a Family High Court, a Family Circuit Court and a Family District Court.
Supporting the Game Changer campaign, a three-year initiative led by Ruhama, in partnership with the GAA and the Men’s Development Network, using sports-based advocacy to raise awareness of gender-based violence.
Convening of a National Consent Forum.
Engagement with the Central Statistics Office (CSO) to scope the development of a Domestic Violence survey to commence in 2025.
According to an internal inspection, undertaken by HSE auditors, on emergency, elective and day procedures at Tipperary University Hospital (TUH); a listing used to ensure HSE safe surgery is being followed, was not located in healthcare records. The failure was discovered following a random sample, taken of 15 patients, latter who had undergone surgical procedures at TUH, Clonmel, Co Tipperary, just last year.
The HSE audit report revealed that it could only provide limited assurance regarding the adequacy and effective governance relating to risk management and the internal control system, at the hospital, when it came to HSE strict policy on safe surgery.
HSE auditors had carried out a retrospective random sample on healthcare records of 15 patients out of a total of 96. Same had undergone surgery or an endoscopy at TUH, over a seven-day period in July 2024. Same audit was undertaken to check that planned surgery was clearly documented and that consent was obtained and recorded for each surgical procedure.
While, TUH had amalgamated aspects of the required checklist into its care plans, latter recommended in the HSE’s National Policy and Procedure for Safe Surgery; the audit found that the HSE’s actual checklist was not found in any medical records reviewed, in relation to the auditors random sample of 15 procedures which had been carried out on site within the hospital.
The report stated that there was a risk that variances between the hospital’s care plans and the official checklist “may result in sub-optimal implementation” of the HSE’s policy on safe surgery “with potential adverse consequences for patients.“
Among questions on the checklist which were not included in the HSE’s recommended care plan were: (A) If the procedure had been confirmed with a parent or guardian in the case of children and if prophylactic antibiotics were required. (B) Failure to check if a healthcare record number matched the number on the patient’s wristband or if protocols were in place if the patient suffered unexpected blood loss. (C) TUH included some questions that were completed after an anaesthetic was administered, which should have been carried out beforehand under the rules as set out in the HSE checklist. (D)TUH was unable to provide records about the number of medical staff who had completed a mandatory course on safe surgery.
The audit further concluded that recommended pre-surgery briefings among medical staff at TUH Clonmel, resembled “nursing huddles” as opposed to multidisciplinary briefings, of which not all members of the theatre team were found to be present at such meetings. The report also noted that non-attendance of key members could result in critical information not being properly transferred, thus resulting in potential harm to patients.
The HSE auditors issued a total of four recommendations, including that all components of the HSE’s checklist for safe surgery be incorporated into the relevant care plans at TUH, or, alternatively that the checklist be adopted as a standalone document by the hospital.
TUH management have now agreed to the implementation of all the recommendations conveyed by the HSE audit.
FSAI warn of undeclared almonds in a batch of mispacked Dunnes Stores Luxury Apple Pie
Alert Summary dated Monday, 16th June 2025.
Allergy Alert Notification: 2025.A23 Allergen: Nuts Product Identification: Dunnes Stores Luxury Apple Pie; pack size: 750g Batch Code: 242; best before date: 16/06/2025 Country Of Origin: Ireland
Message: The above batch of Dunnes Stores Luxury Apple Pie is being recalled as some packs have been mispacked with Dunnes Stores Luxury Pear and Almond Pie. The product contains almonds which are not declared on the label. This may make the batch unsafe for consumers who are allergic to or intolerant of almonds, and therefore, these consumers should not eat the implicated batch.
Wholesalers/Distributors: Same are requested to contact their affected customers and recall the implicated batch and provide a point-of-sale recall notice to their retail customers.
Retailers: Same are requested to remove the implicated batch from sale and display recall notices at point-of-sale.
Consumers: Consumers are advised not to administer the implicated batch to infants or children.
This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish.AcceptRead More
Privacy & Cookies Policy
Privacy Overview
This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
Recent Comments